Sandoz Group: Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines

Related Keywords

Switzerland ,United States ,American ,Swiss ,Claire Dabreu ,Karenm King ,Chris Lewis ,Joerge Allgaeuer ,American Cancer Society ,Amgen Inc ,European Medicines Agency ,European Commission ,Swiss Exchange Listing ,International Osteoporosis Foundation ,Exchange Listing ,Sandoz Chief Scientific Officer ,Media Release ,Medicines Agency ,Calcium Sandoz ,Media Relations ,Ihr Portfolio ,